opnMe News

Let´s live innovation. Want to know the latest news and trends? Read more

Subscribe to our newsletter to stay up to date with latest developments

Latest news

9 July 2019

Targeted protein degradation by exploiting the ubiquitin proteasome system has recently emerged as a new and promising modality of intervention in drug discovery. One approach to induce protein degradation is to design hetero bifunctional molecules called proteolysis-targeting chimeras – also known as PROTACs. In combination with structure-based drug design, it has allowed researchers to aim at new targets which were previously deemed “undruggable”.

With BI-3663 and BI-0319 we release two new highly selective PTK2 PROTACs

up
16

18 May 2019

Today, Boehringer Ingelheim has added its well-characterized non-covalent ATP-competitive receptor channel complex (glycine and NMDA binding sites) BIII 277CL to its molecule platform opnMe.com. High selectivity and decent PK properties make BIII 277CL a suitable tool for in vivo validation of NMDA as a therapeutic target.

The winner is NMDA

up
19

17 April 2019

In connection with the 2nd International Symposium on Cathepsin C we have launched today the first of three new Cathepsin C molecules on opnMe.com. These will be featured as part of a talk provided by Marc Grundl, Senior Principal Scientist, Medicinal Chemistry, Boehringer Ingelheim with the title: “Cathepsin C: a challenge for medicinal chemistry”.

BI-9740, 3-D conformation co-crystalized in the Cathepsin C protein

up
19

15 April 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is currently seeking novel applications for its unprecedented, potent and highly selective orally bioavailable BCL6 degrader BI-1136.

Oral BCL6 degrader News Announcement

up
18

8 April 2019

End of 2018, the opnMe core team produced a small movie which outlined the story of opnMe open innovation portal from its conception until its first successes after its launch in November 2017.

up
23

27 March 2019

The opnMe team is pleased to announce the addition of its 30th Molecule 2 Order to the Boehringer Ingelheim open innovation portal. BIII 890CL (crobenetine) is a potent, selective and highly use-dependent sodium channel blocker.

HIV Transcriptase News Announcement

up
20

18 February 2019

Now, scientists from all over world can access our molecule completely free of charge without any shipment costs to pursue further pre-clinical research independently of us.

HIV Transcriptase News Announcement

up
15

11 February 2019

The opnMe team is pleased to announce the addition of BI 224436 to its molecules 2 order program. Now, scientists from all over the world can access our molecule completely free of charge without any shipment costs.

HIV Integrase News Announcement

up
26

21 January 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel applications of its lung-specific gene therapy vector AAV2-L1 in pulmonary diseases.

AAV2-L1 for collaboration

up
18

09 January 2019

Boehringer Ingelheim is to make the BET degrader compound MZ 1 available through its opnMe.com portal. The company actively supports open access in order to boost progress in biomedical and drug discovery research. MZ 1 (created at the University of Dundee) is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal.

read more...

Prof. Dr. Alessio Ciulli, University of Dundee. One of the pioneers in the field of PROTACs